IL17A and neoplasm: Although neutrophils have already been described in patients with tumors,[13] to our knowledge this is the first demonstration of a statistically significant correlation between prevalent high FasL+PD‐L2+ neutrophil subset in human tumors and poor patient prognosis; it is also the first demonstration for Th17 cell‐derived IL‐17A and tumor cell‐derived G‐CSF to collectively induce immunosuppressive neutrophils which inhibit tumor‐specific CD8+ T‐cell immunity.